SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7357-7363

  Chlenski, Alexandre ^a   Liu, Shuqing ^a   Crawford, Susan E ^a   Volpert, Olga V ^a   DeVries, George H ^b   Evangelista, Amy ^a   Yang, Qiwei ^a   Salwen, Helen R ^a   Farrer, Robert ^b   Bray, James ^a   Cohn, Susan L ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN; PIGMENT EPITHELIUM DERIVED FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHWANN CELL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; OSTEONECTIN; SCHWANN CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037115291     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Alvarado, C. S., London, W. B., Look, A. T., Brodeur, G. M., Altmiller, D. H., Thorner, P. S., Joshi, V. V., Rowe, S. T., Nash, M. B., Smith, E. I., Castleberry, R. P., and Cohn, S. L. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol., 22, 197-205, 2000.
2. Perez, C. A., Matthay, K. K., Atkinson, J. B., Seeger, R. C., Shimada, H., Haase, G. M., Stram, D. O., Gerbing, R. B., and Lukens, J. N. Biological variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group Study. J. Clin. Oncol., 18: 18-26, 2000.
3. Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., and Reynolds, C. P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N. Engl. J. Med., 341: 1165-1173, 1999.
4. Brodeur, G. M., and Maris, J. M. Neuroblastoma. In: P. A. Pizzo and D. G. Poplack (eds.), Principles and Practice of Pediatric Oncology, 4th Ed., pp. 895-937. Philadelphia: Lippincott-Raven, 2001.
5. Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castle, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., Hedborg, F., Kaneko, M., Kemshead, J., Lampert, F., Lee, R. E. J., Look, A. T., Pearson, A. D. J., Philip, T., Roald, B., Sawada, T., Seeger, R. C., Tsuchida, Y., and Voute, P. A. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol., 11: 1466-1477, 1993.
6. Evans, A. E., D'Angio, G. J., Propert, K., Anderson, J., and Hann, H-W. L. Prognostic factors in neuroblastoma. Cancer (Phila.), 59: 1853-1859, 1987.
7. Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., and Castleberry, R. P. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer (Phila.), 86: 364-372, 1999.
8. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.
9. Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., and Brodeur, G. M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastema. N. Engl. J. Med., 328: 847-854, 1993.
10. Maris, J. M., Weiss, M. J., Guo, C., Gerbing, R. B., Stram, D. O., White, P. S., Hogarty, M. D., Sulman, E. P., Thompson, P. M., Lukens, J. N., Matthay, K. K., Seeger, R. C., and Brodeur, G. M. Loss of heterozygosity at Ip36 independently predicts for disease progression, but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group Study. J. Clin. Oncol., 18: 1888-1899, 2000.
11. Caron, H., van Sluis, P., de Kraker, J., Bokkerink, J., Egeler, M., Laureys, G., Slater, R., Westerveld, A., Voute, P. A., and Versteeg, R. Allelic loss of chromosome Ip as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med., 334: 225-230, 1996.
12. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., and Speleman, F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340: 1954-1961, 1999.
13. Look, A. T., Hayes, F. A., Shuster, J. J., Douglass, E. C., Castleberry, R. P., Bowman, L. C., Smith, E. I., Brodeur, G. M. Clinical relevance of tumor cell pleidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J. Clin. Oncol., 9: 581-591, 1991.
14. Meitar, D., Crawford, S. E., Rademaker, A. W., and Cohn, S. L. Tumor angiogenesis correlates with metastatic disease. N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14: 405-414, 1996.
15. Eggert, A., Ikegaki, N., Kwiatkowski, J., Zhao, H., Brodeur, G. M., and Himelstein, B. P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 6: 1900-1908, 2000.
16. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res., 60: 712-721, 2000.
17. Breit, S., Ashman, K., Wilting, J., Rossler, J., Hatzi, E., Fotsis, T., and Schweigerer, L. The N-myc oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res., 60: 4596-4601, 2000.
18. Eggert, A., Grotzer, M. A., Ikegaki, N., Liu, X. G., Evans, A. E., and Brodeur, G. M. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res., 62: 1802-1808, 2002
19. Davidoff, A. M., Leary, M. A., Ng, C. Y., and Vanin, E. F. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg., 36: 30-36, 2001.
20. Katzenstein, H. M., Rademaker, A. W., Senger, C., Salwen, H., Nguyen, N., and Cohn, S. L. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res., 5: 4273-4278, 1999.
21. Nagabuchi, E., Van der Kolk, W. E., Une, Y., and Ziegler, M. M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Pediatr, Surg., 32: 287-293, 1997.
22. Wassberg, E., Pahlman, S., Westlin, J. E., and Christofferson, R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr. Res., 41: 327-333, 1997.
23. Shusterman, S., Grupp, S. A., Barr, R., Carpentieri, D., Zhao, H., and Maris, J. M. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res., 7: 977-984, 2001.
24. Shimada, H., Chatten, J., Newton, W. A., Jr., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., and Misugi, K. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst. (Bethesda), 73: 405-416, 1984.
25. Ambros, I. M., Zellner, A., Roald, B., Amann, G., Ladenstein, R., Printz, D., Gadner, H., and Ambros, P. F. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N. Engl. J. Med., 334: 1505-1511, 1996.
26. Mora, J., Cheung, N. K., Juan, G., Illei, P., Cheung, I., Akram, M., Chi, S., Ladanyi, M., Cordon-Cardo, C., and Gerald, W. L. Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res., 61: 6892-6898, 2001.
27. Kwiatkowski, J. L., Rutkowski, J. L., Yamashiro, D. J., Tennekoon, G. I., and Brodeur, G. M. Schwann cell-conditioned medium promotes neuroblastoma survival and differentiation. Cancer Res., 58: 4602-4606, 1998.
28. Ambros, I. M., Attarbaschi, A., Rumpler, S., Luegmayr, A., Turkof, E., Gadner, H., and Ambros, P. F. Neuroblastoma cells provoke Schwann cell proliferation in vitro. Med. Pediatr. Oncol., 36: 163-168, 2001.
29. Huang, D., Rutkowski, J. L., Brodeur, G. M., Chou, P. M., Kwiatkowski, J. L., Babbo, A., and Cohn, S. L. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res., 60: 5966-5971, 2000.
30. Crawford, S. E., Stellmach, V., Ranalli, M., Huang, X., Huang L., Volpert, O. De Vries, G. H., Abramson, L. P., and Bouck, N. Pigment epithelium-derived factor (PEDF) in nearoblastoma: A multifunctional mediator of Schwann cell antitumor activity. J. Cell Sci., 114: 4421-4428, 2001.
31. Sage, H., Johnson, C., and Bornstein, P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J. Biol. Chem., 259: 3993-4007, 1984.
32. Bolander, M. E., Young, M. F., Fisher, L. W., Yamada, Y., and Termine, J. D. Osteonectin cDNA sequence reveals potential binding regions for calcium and hydroxyapatite and shows homologies with both a basement membrane protein (SPARC) and a serine proteinase inhibitor (ovomucoid). Proc. Natl. Acad. Sci. USA, 85: 2919-2923, 1988.
33. Villarreal, X. C., Mann, K. G., and Long, G. L. Structure of human osteonectin based upon analysis of cDNA and genomic sequences, Biochemistry, 28: 6483-6491, 1989.
34. Sage, H., Vernon, R. B., Decker, J., Funk, S., and Iruela-Arispe, M. L. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J. Histochem. Cytochem., 37: 819-829, 1989.
35. Mundlos, S., Schwahn, B., Reichert, T., and Zabel, B. Distribution of ostconectin mRNA and protein during human embryonic and fetal development. J. Histochem. Cytochem. 40: 283-291, 1992.
36. Lane, T. F., and Sage, E. H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J., 8: 163-173, 1994.
37. 2+-dependent binding to the extracellular matrix. J. Cell Biol., 109: 341-356, 1989.
38. Hasselaar, P., and Sage, E. H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem., 49: 272-283, 1992.
39. Kupprion, C., Motamed, K., and Sage, E. H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem., 273: 29635-29640, 1998.
40. Mettouchi, A., Cabon, F., Montreau, N., Vernier, P., Mercier, G., Blangy, D., Tricoire, H., Vigier, P., and Binetruy, B. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J., 13: 5668-5678, 1994.
41. Vial, E., and Castellazzi, M. Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo. Oncogene, 19: 1772-1782, 2000.
42. Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., Mordoh, J., and Podhajcer, O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3: 171-176, 1997.
43. Funk, S. E., and Sage, E. H. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J. Cell. Physiol., 154: 53-63, 1993.
44. Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S., Cheung, K. K., Berkowitz, R. S., and Mok, S. C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol., 159: 609-622, 2001.
45. Rutkowski, J. L., Kirk, C. J., and Lerner, M. A. Purification and expansion of human Schwann cells in vitro. Nat. Med., 1: 80-83, 1995.
46. Foley, J., Cohn, S. L., Salwen, H. R., Chagnovich, D., Cowan, J., Mason, K. L., and Parysek, L. M. Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res., 51: 6338-6345, 1991.
47. Cohn, S. L., Salwen, H., Quasney, M. W., Ikegaki, N., Cowan, J. M., Herst, C. V., Kennett, R. H., Rosen, S. T., DiGiuseppe, J. A., and Brodeur, G. M. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene, 5: 1821-1827, 1990.
48. Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. Phenotypic diversification in human neuroblastoma cells: Expression of distinct neural crest lineages. Cancer Res., 49: 219-225, 1989.
49. Reynolds, C. P., Biedler, J. L., Spengler, B. A., Reynolds, D. A., Ross, R. A., Frenkel, E. P., and Smith, R. G. Characterization of human neuroblastoma cell lines established before and after therapy. J. Natl. Cancer Inst. (Bethesda), 76: 375-387, 1986.
50. Manohar, C. F., Short, M. L., Nguyen, A., Nguyen, N. N., Chagnovich, D., Yang, Q., and Cohn, S. L. HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA. J. Biol. Chem., 277: 1967-1973, 2002.
51. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: Procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
52. Polverini, P. J., Bouck, N. P., and Rastinejad, F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol., 198: 440-450, 1991.
53. Chen, S. Y., Yang, A. G., Chen, J. D., Kute, T., King, C. R., Collier, J., Cong, Y., Yao, C., and Huang, X. F. Potent antitumour activity of a new class of turnoutspecific killer cells. Nature (Lond.), 385: 78-80, 1997.
54. Spengler, B. A., Lazarova, D. L., Ross, R. A., and Biedler, J. L. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells. Oncol. Res., 9: 467-476, 1997.
55. Chagnovich, D., and Cohn, S. L. Binding of a 40-kDa protein to the N-myc 3′ untranslated region correlates with enhanced N-myc expression in human neuroblastoma. J. Biol. Chem., 271: 33580-33586, 1996.
56. Thiele, C. J., Reynolds, C. P., and Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature (Lond.), 313: 404-406, 1985.
57. Schubert, D., and Jacob, F. 5-Bromodeoxyuridine-induced differentiation of a neuroblastoma. Proc. Natl. Acad. Sci. USA, 67: 247-254, 1970.
58. Reynolds, C. P., and Maples, J. Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines. Prog. Clin. Biol. Res., 175: 13-37, 1985.
59. Sidell, N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst. (Bethesda), 68: 589-596, 1982.
60. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., and Bouck, N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol., 122: 497-511, 1993.
61. Nicosia, R. F., and Tuszynski, G. P. Matrix-bound thrombospondin promotes angiogenesis in vitro. J. Cell Biol., 124: 183-193, 1994.
62. Young, M. F., Bolander, M. E., Day, A. A., Ramis, C. I., Robey, P. G., Yamada, Y., and Termine, J. D. Osteonectin mRNA: Distribution in normal and transformed cells. Nucleic Acids Res., 14: 4483-4497, 1986.
63. 2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA, 88: 2648-2652, 1991.
64. Sage, E. H. Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. Biochem. Cell Biol., 70: 579-592, 1992.
65. Bradshaw, A. D., and Sage, E. H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Investig., 107: 1049-1054, 2001.
66. Lane, T. F., Iruela-Arispe, M. L., Johnson, R. S., and Sage, E. H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol., 125: 929-943, 1994.
67. Bellahcene, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
68. Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.
69. Ledda, F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., and Podhajcer, O. L. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Investig. Dermatol., 108: 210-214, 1997.
70. Rempel, S. A., Ge, S., and Gutierrez, J. A. SPARC: A potential diagnostic marker of invasive meningiomas. Clin. Cancer Res., 5: 237-241, 1999.
71. ++-binding sites modulate cell shape. J. Cell Biol., 111: 3065-3076, 1990.
72. Jimenez, B., and Volpert, O. V. Mechanistic insights on the inhibition of tumor angiogenesis. J. Mol. Med., 78: 663-672, 2001.
73. Volpert, O. V. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: A dynamic balance. Cancer Metastasis Rev., 19: 87-92, 2000.
74. Ara, T., Fukuzawa, M., Kusafuka, T., Komoto, Y., Oue, T., Inoue, M., and Okada, A. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: Association with tumor progression and clinical outcome. J. Pediatr. Surg., 33: 1272-1278, 1998.
75. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
76. Volpert, O. V., Dameron, K. M., and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene, 14: 1495-1502, 1997.
77. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Wash. DC), 265: 1582-1584, 1994.
78. Rastinejad, F., Polverini, P. J., and Bouck, N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 56: 345-355, 1989.
79. Ray, J. M., and Stetler-Stevenson, W. G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J., 7: 2062-2072, 1994.